

1 **Distinct explanations underlie gene-environment interactions in the UK Biobank**

2 Arun Durvasula^{1,2,3,4,5} and Alkes L. Price^{4,5,6}

- 3 1. Center for Genetic Epidemiology, Department of Population and Public Health Sciences,
- 4 Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
- 5 2. Department of Genetics, Harvard Medical School, Cambridge, MA, USA
- 6 3. Department of Human Evolutionary Biology, Harvard University, Cambridge, MA, USA
- 7 4. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard,
- 8 Cambridge, MA, USA
- 9 5. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA,
- 10 USA
- 11 6. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA,
- 12 USA

13
14 Correspondence: arun.durvasula@med.usc.edu or aprice@hsph.harvard.edu

15 **Abstract**

16
17
18 The role of gene-environment (GxE) interaction in disease and complex trait architectures is
19 widely hypothesized, but currently unknown. Here, we apply three statistical approaches to
20 quantify and distinguish three different types of GxE interaction for a given disease/trait and E
21 variable. First, we detect locus-specific GxE interaction by testing for genetic correlation (r_g) < 1
22 across E bins. Second, we detect genome-wide effects of the E variable on genetic variance by
23 leveraging polygenic risk scores (PRS) to test for significant PRSxE in a regression of
24 phenotypes on PRS, E, and PRSxE, together with differences in SNP-heritability across E bins.
25 Third, we detect genome-wide proportional amplification of genetic and environmental effects as
26 a function of the E variable by testing for significant PRSxE with no differences in SNP-
27 heritability across E bins. Simulations show that these approaches achieve high sensitivity and
28 specificity in distinguishing these three GxE scenarios. We applied our framework to 33 UK
29 Biobank diseases/traits (average $N=325K$) and 10 E variables spanning lifestyle, diet, and other
30 environmental exposures. First, we identified 19 trait-E pairs with r_g significantly < 1 (FDR<5%)
31 (average $r_g=0.95$); for example, white blood cell count had $r_g=0.95$ (s.e. 0.01) between smokers
32 and non-smokers. Second, we identified 28 trait-E pairs with significant PRSxE and significant
33 SNP-heritability differences across E bins; for example, type 2 diabetes had a significant PRSxE
34 for alcohol consumption ($P=1e-13$) with 4.2x larger SNP-heritability in the largest versus
35 smallest quintiles of alcohol consumption ($P<1e-16$). Third, we identified 15 trait-E pairs with
36 significant PRSxE with no SNP-heritability differences across E bins; for example, triglyceride
37 levels had a significant PRSxE effect for composite diet score ($P=4e-5$) with no SNP-heritability
38 differences. Analyses using biological sex as the E variable produced additional significant
39 findings in each of the three scenarios. Overall, we infer a substantial contribution of GxE and
40 GxSex effects to disease and complex trait variance.

43 Introduction

44

45 Although gene-environment (GxE) interactions have long been thought to impact the
46 genetic architecture of diseases and complex traits¹⁻⁴, the overall contribution of these effects
47 remains unclear. Previous studies have detected GxE at a limited number of specific loci⁵⁻⁷
48 (including studies that associated genotype to phenotypic variance without knowing the
49 underlying E variable⁸⁻¹²). Previous studies have also proposed variance components methods
50 for detecting genome-wide contributions of GxE to disease heritability¹³⁻¹⁸, but these methods
51 have not been applied at biobank scale across a broad range of disease/traits. Thus, the overall
52 contribution of GxE to disease/trait architectures is currently unknown. In addition, the relative
53 importance of different types of GxE (e.g., locus-specific GxE, genome-wide effects of E on
54 genetic variance, genome-wide effects of E on both genetic and environmental variance) is
55 currently unclear. Studies of GxSex interaction face similar challenges¹⁹⁻²⁴.

56

57 Here, we apply three statistical approaches to quantify and distinguish three different
58 types of GxE interaction for a given disease/trait and E variable. First, we detect locus-specific
59 GxE interaction by testing for genetic correlation²⁵ (r_g) < 1 across E bins. Second, we detect
60 genome-wide effects of the E variable on genetic variance by leveraging polygenic risk
61 scores^{26,27} (PRS) to test for significant PRSxE^{28,29} in a regression of phenotypes on PRS, E, and
62 PRSxE, together with differences in SNP-heritability³⁰⁻³⁴ across E bins. Third, we detect
63 genome-wide proportional amplification of genetic and environmental effects as a function of the
64 E variable by testing for significant PRSxE with no differences in SNP-heritability across E bins.
65 We analyze 33 diseases/traits from the UK Biobank³⁵ (average $N=325K$), quantifying the
66 contributions of each type of GxE effect across 10 E variables spanning lifestyle, diet, and other
67 environmental exposures, as well as contributions of GxSex effects.

68

69 Results

70

71 *Overview of methods*

72

73 We aim to detect genome-wide GxE, i.e., GxE effects aggregated across the genome. We
74 consider three potential scenarios that give rise to genome-wide GxE for a given disease/trait and
75 E variable (**Figure 1a**). In the first scenario (Imperfect genetic correlation), there is an imperfect
76 genetic correlation across E bins due to different SNP effect sizes in different E bins. In the
77 second scenario (Varying genetic variance), there are differences in SNP-heritability across E
78 bins due to uniform amplification of SNP effect sizes across E bins; the environmental variance
79 may either remain constant or vary across E bins. In the third scenario (proportional
80 amplification), the genetic and environmental variance vary proportionately across E bins due to
81 proportionate scaling of SNP effect sizes and environmental effect sizes across E bins, so that
82 SNP-heritability remains the same across E bins. We conceptualize these three scenarios as
83 acting at different levels in a hierarchy that leads from genetic variants to pathways to disease
84 (see **Discussion**).

85

86 The three scenarios can be formalized under the following model:

87

$$y_j = \sum_i x_{ij}\beta_i + \sum_i \gamma_i x_{ij}E_j + \sum_i \xi x_{ij}\beta_i E_j + \varepsilon_j + \eta \varepsilon_j E_j, \#(1)$$

88
89 where y_j denotes the phenotype for individual j , x_{ij} denotes the genotype of individual j at SNP
90 i , β_i denotes the effect size of SNP i , γ_i denotes SNP-specific GxE effects, E_j denotes the E
91 variable value for individual j , ξ quantifies the amplification of genetic effects across E values,
92 ε_j denotes environmental effects, and η quantifies the amplification of environmental effects
93 across E values. In Scenario 1, γ_i will be nonzero. In Scenario 2, ξ will be nonzero. In Scenario
94 3, ξ and η will be nonzero and equal.

95
96 In this study, we apply three statistical approaches to UK Biobank data to detect genome-
97 wide GxE, analyzing 33 diseases/traits (average $N=325K$) and 10 environmental variables as
98 well as biological sex (**Figure 1b**). First, we detect Imperfect genetic correlation (Scenario 1) by
99 estimating the genetic correlation of effect sizes between sets of individuals binned on their E
100 variables using cross-trait LD Score regression²⁵ (LDSC) (**Methods**). For non-binary E
101 variables, we estimate the genetic correlation between the most extreme quintiles of the E
102 variable; for binary E variables, we estimate the genetic correlation between individuals in each
103 E bin. Second, we employ PRSxE regression^{28,29}, defined as a regression of the phenotype on the
104 PRS^{26,27} multiplied by the E variable across individuals, to detect both Varying genetic variance
105 (Scenario 2) and Proportional amplification (Scenario 3) (**Methods**); we note that PRSxE
106 regression is not sensitive to changes in environmental variance only (**Methods**). We use PRS
107 computed by PolyFun-pred²⁷ for all analyses involving PRS. We do not standardize the E
108 variables, and we correct for main and interaction effects of several covariates (**Methods**).
109 Finally, we distinguish between Scenario 2 and Scenario 3 by estimating the SNP-heritability
110 within each E bin using BOLT-REML³³ and testing for significant differences between E bins
111 (most extreme quintiles for non-binary E variables; each bin for binary E variables).

112
113 We assign a trait-E pair to Scenario 1 if it has a genetic correlation across E bins < 1
114 (regardless of whether it differs in SNP-heritability or has a significant PRSxE regression term);
115 we assign a trait-E pair to Scenario 2 if it has both a significant PRSxE regression term and a
116 significant difference in SNP-heritability across E bins; finally, we assign a trait-E pair to
117 Scenario 3 if it has a significant PRSxE regression term with no significant difference in SNP-
118 heritability across E bins (**Figure 1c**). We note that for some trait-E pairs, we detected both
119 locus-dependent GxE (Scenario 1) and non-locus-dependent GxE (Scenario 2 or Scenario 3). We
120 estimate the excess disease/trait variance explained by genome-wide GxE as follows. In Scenario
121 1, we transform the estimate of genetic correlation across E bins to the variance scale (**Methods**;
122 **Supplementary Note**). In Scenario 2 and Scenario 3, we approximate the relative amount of trait
123 variance explained by GxE effects (relative to the genetic variance) as the trait variance
124 explained by PRSxE effects divided by the trait variance explained by the PRS; this
125 approximation is valid under a model in which the PRSxE effects are proportional to the GxE
126 effects (**Methods**). All reported variances are transformed to the liability scale for disease traits.
127 We have released open-source software implementing the above approaches (see Code
128 Availability), as well as their output from this study (see Data Availability).

129
130 *Simulations*

131

132 We performed simulations of the three Scenarios to evaluate the properties of the three
133 statistical approaches. We assigned individuals to one of two E bins and simulated genetic
134 effects at 10,000 causal SNPs based on the Scenario and E bin. We simulated sample sizes
135 specific to each statistical approach to match our real data analyses (see below). In Scenario 1,
136 we set the SNP-heritability to 25% and varied the genetic correlation from 99% to 94%. In
137 Scenario 2, we set the genetic correlation to 100%, set the SNP-heritability to 25% in one E bin,
138 and varied the SNP-heritability from 26% to 30% in the other E bin. In Scenario 3, we amplified
139 the (genetic and environmental components of) phenotypes in one E bin by a range of values
140 from 1.025 to 1.1. In each Scenario, we report the proportion of significant tests ($P < 0.05$, which
141 is fairly similar to our significance threshold for real traits; see below) for each of our three
142 approaches: Genetic correlation ($N=67K$ individuals per E bin), PRSxE regression (training
143 $N=337K$, testing $N=49K$), and SNP-heritability by E ($N=67K$ individuals per E bin). Because
144 linkage disequilibrium (LD) does not impact GxE effects, we simulated genotypes without LD.
145 We adjusted the methods used in our simulations accordingly. For Genetic correlation, we used
146 cross-trait LD score regression in the special case of no LD²⁵. For PRSxE regression, we used a
147 simple shrinkage estimator in the special case of no LD to compute PRS. For SNP-heritability by
148 E, we estimated SNP-heritability using LD score regression in the special case of no LD³⁶.
149 Further details of the simulation framework are provided in the **Methods** section.

150
151 In Scenario 1, the Genetic correlation approach reported a significant test in 93% of
152 simulations when the true genetic correlation was 97% or smaller, whereas the PRSxE regression
153 and SNP-heritability by E approaches were well-calibrated (**Figure 2a** and **Supplementary**
154 **Table 1**). In Scenario 2, the PRSxE regression approach reported a significant test in 88% of
155 simulations when the SNP-heritability difference was 4% or larger, and the SNP-heritability by E
156 approach reported a significant test in more than 88% of simulations when the SNP-heritability
157 difference was 2% or larger, whereas the Genetic correlation approach was well-calibrated
158 (**Figure 2b** and **Supplementary Table 1**). In Scenario 3, the PRSxE regression approach
159 reported a significant test in 88% of simulations when the proportional amplification was 1.075
160 or larger, whereas the Genetic correlation and SNP-heritability by E approaches were well-
161 calibrated (**Figure 2c** and **Supplementary Table 1**). In null simulations (heritable trait with no
162 GxE), all three statistical approaches were well-calibrated (**Supplementary Figure 1**).

163
164 We compared our framework with GxEMM¹⁶, a variance components-based framework
165 that implements two GxE tests: 1) a test for polygenic GxE under homoskedasticity (GxEMM-
166 Hom), and 2) a test for polygenic GxE under heteroskedasticity (GxEMM-Het). We note that
167 GxEMM-Hom and GxEMM-Het do not precisely map to the 3 scenarios that we study here. In
168 addition, because GxEMM is a variance components-based framework, it is currently unable to
169 scale to biobank-sized datasets. We evaluated the performance of GxEMM on a sample size of
170 10,000 individuals, as in the simulations of ref. ¹⁶. We evaluated our statistical approaches using
171 matched sample sizes, with 5,000 individuals per binary E bin and 10,000 test individuals for
172 PRSxE regression. We kept the training data set size the same as in our main simulations
173 ($N=337K$). In Scenario 1, the GxEMM-Hom test reported a similar proportion of significant tests
174 as the Genetic correlation approach, whereas the GxEMM-Het test reported roughly half as many
175 significant tests (**Supplementary Figure 2**). In Scenario 2, the GxEMM-Het test was less
176 powerful than the PRSxE regression and SNP-heritability by E approaches, whereas the
177 GxEMM-Hom test was well-calibrated (**Supplementary Figure 2**). In Scenario 3, the GxEMM-

178 Het test was less powerful than the PRSxE regression approach, whereas the GxEMM-Hom test
179 was well-calibrated (**Supplementary Figure 2**). Thus, at sample sizes that permit computational
180 tractability, GxEMM is generally less powerful than our framework (and cannot distinguish
181 Scenario 2 and Scenario 3).

182
183 Our framework also estimates the excess disease/trait variance explained by GxE effects,
184 beyond what is explained by additive effects (for brevity, we refer to this as variance explained).
185 We determined that estimates of disease/trait variance explained were accurate in each of
186 Scenario 1 (regression slope = 0.98; **Supplementary Figure 3a**), Scenario 2 (regression slope =
187 0.85; **Supplementary Figure 3b**), and Scenario 3 (regression slope = 1.05; **Supplementary**
188 **Figure 3c**). We note that in both Scenario 2 and Scenario 3, G effects are correlated with GxE
189 effects, as a correlation between genetic variance (G^2) and the E variable implies a correlation
190 between G and GxE. Current variance components methods do not account for this correlation
191 and may therefore produce biased estimates of variance explained by GxE; we have verified this
192 in simulations (**Supplementary Table 2**). Here, we report the difference in variance explained
193 by a model including an interaction term (PRS+PRSxE terms) over a base model (PRS only) that
194 does not include an interaction term, which is robust to this correlation (**Methods** and
195 **Supplementary Figure 3**).

196
197 In summary, our simulations indicate that our statistical approaches attain high sensitivity
198 and specificity in classifying trait-E pairs into the distinct scenarios of GxE considered here and
199 produce accurate estimates of excess trait variance explained by GxE.

200
201 *Identifying gene-environment interactions across 33 diseases/complex traits and 10 E variables*

202
203 We analyzed individual-level data for $N=384K$ unrelated European-ancestry individuals
204 from the UK Biobank³⁵. We selected 33 highly heritable (z-score for nonzero SNP-heritability³⁶
205 > 6) and relatively independent (squared genetic correlation²⁵ < 0.5) diseases and traits
206 (**Supplementary Table 3**). In addition, we selected 10 relatively independent E variables
207 spanning lifestyle, diet, and other environmental exposures ($r^2 < 0.1$; primarily from ref. ¹⁴;
208 **Supplementary Figure 4**; see **Methods**). We note that these E variables are all significantly
209 heritable, although the heritability tends to be low (mean SNP-heritability = 6%, max SNP-
210 heritability = 15%; **Supplementary Table 4**). We assessed statistical significance using a
211 threshold of $FDR < 5\%$ across traits and E variables for a given statistical test (see **Methods**); in
212 practice, this FDR threshold corresponded to a P-value threshold of ≈ 0.01 , which is fairly
213 similar to our simulations.

214
215 Trait-E pairs assigned to Scenario 1 (Imperfect genetic correlation) are reported in **Figure**
216 **3a** and **Supplementary Table 5**. We identified 19 trait-E pairs with genetic correlation
217 significantly less than 1 ($FDR < 5\%$; average genetic correlation: 0.95), implicating 12 of 33 traits
218 and 9 of 10 E variables tested. The implicated traits included 9 blood cell and biochemistry traits,
219 as well as height, BMI, and asthma. On average, these interactions explained 0.27% of
220 disease/trait variance across all traits analyzed. The lowest significant genetic correlation was
221 0.85 (se=0.06) for asthma x time spent watching television, explaining 1.5% of trait variance.
222 The significant GxE interaction for BMI and smoking status (explaining 0.4% of trait variance)
223 was consistent with results from ref. ¹⁴. Trait-E pairs assigned to Scenario 2 (Varying genetic

224 variance) are reported in **Figure 3b** and **Supplementary Table 5**. We identified 28 trait-E pairs
225 with significant PRSxE interaction (FDR<5%) and a significant SNP-heritability by E test
226 (FDR<5%), implicating 13 of 33 traits and 9 of 10 E variables tested. On average, these
227 interactions explained 2.6% of disease/trait variance across all traits analyzed; the variance
228 explained by GxE effects was larger for binary traits than for quantitative traits (see **Discussion**).
229 Because standard interaction tests can be anti-conservative due to unmodeled
230 heteroskedasticity³⁷, we repeated our PRSxE interaction analysis using Huber-White variance
231 estimators^{38,39} (**Methods**). We determined that results were highly concordant with our primary
232 PRSxE interaction analysis (mean Pearson correlation in p-values for interaction across trait-E
233 pairs: 97%; **Supplementary Table 6**), suggesting that our findings are not driven by unmodeled
234 heteroskedasticity. Trait-E pairs assigned to Scenario 3 (Proportional amplification) are reported
235 in **Figure 3c** and **Supplementary Table 5**. We identified 15 trait-E pairs with significant PRSxE
236 interaction (FDR<5%) but a non-significant SNP-heritability by E test (FDR<5%), implicating
237 11 of 33 traits and 9 of 10 E variables tested. On average, these interactions explained 0.13% of
238 disease/trait variance across all traits analyzed.

239
240 We checked whether any trait-E pairs were assigned to more than one Scenario. We
241 determined that 2 trait-E pairs were assigned to both Scenario 1 and Scenario 2 (BMI x alcohol
242 consumption and BMI x Townsend deprivation index); 0 trait-E pairs were assigned to both
243 Scenario 1 and Scenario 3; and 0 trait-E pairs were assigned to both Scenario 2 and Scenario 3
244 (which is not possible based on their definition). We also identified 108 trait-E pairs with a
245 significant SNP-heritability by E test but non-significant PRSxE interaction (**Supplementary**
246 **Table 7**); our primary interpretation is that this is due to changes in environmental variance
247 rather than GxE interaction (**Methods**), but we cannot exclude the possibility that this is due to
248 GxE interaction that we have incomplete power to detect.

249
250 Examples of trait-E pairs assigned to each scenario are reported in **Figure 4** and
251 **Supplementary Table 8**. First, white blood cell count x smoking status was assigned to Scenario
252 1 (**Figure 4a**). The Genetic correlation approach estimated a genetic correlation between
253 smokers and non-smokers of 0.95, which is significantly less than 1 (P=6.7e-7; FDR < 5%),
254 explaining 0.5% of the variance of white blood cell count (vs. SNP-heritability of 30%). On the
255 other hand, the PRSxE regression approach (P=0.46) and SNP-heritability x E approach (P=0.39)
256 produced non-significant results. We note that smokers had 0.09 s.d. higher mean white blood
257 cell count than non-smokers (T-test P<1e-16), as previously reported⁴⁰. Second, type 2 diabetes x
258 alcohol consumption was assigned to Scenario 2 (**Figure 4b**). The PRSxE regression approach
259 (P=1e-13) and SNP-heritability x E approach (SNP-heritability (liability scale) of 0.45 for
260 highest E quintile vs. 0.38 for lowest E quintile; P<1e-16) both produced significant results
261 (FDR < 5%), explaining 18% of the variance of type 2 diabetes (vs. SNP-heritability of 35%).
262 On the other hand, the genetic correlation approach produced a non-significant result (P=0.15).
263 We note that the prevalence of type 2 diabetes varied with alcohol consumption (6% in highest E
264 quintile vs. 3% in lowest E quintile; P<2e-16), as previously reported⁴¹. Third, WHRadjBMI x
265 time spent watching television (TV time) was assigned to Scenario 3 (**Figure 4c**). The PRSxE
266 regression approach produced a significant result (P=5e-3; FDR < 5%), explaining 0.95% of the
267 variance of WHRadjBMI. On the other hand, the genetic correlation approach (P=0.29) and
268 SNP-heritability x E approach (P=0.08) produced non-significant results. We note that
269 WHRadjBMI and TV time were correlated ($r = 0.08$, P<1e-16).

270

271 In summary, we detected GxE interaction in each of the three scenarios across the 33
272 diseases/traits and 10 E variables analyzed. We estimate that these GxE effects explain 3.0% of
273 disease/trait variance across all traits analyzed (s.e. 1.5% across traits), compared to SNP-
274 heritability of 29% (s.e. 3% across traits).

275

276 *Identifying gene-sex interactions across 33 diseases/complex traits*

277

278 We analyzed the same 33 diseases/traits for GxSex interaction using the same 3 statistical
279 approaches. Traits assigned to Scenario 1 (Imperfect genetic correlation) are reported in **Figure**
280 **5a** and **Supplementary Table 9**. We identified 22 traits with cross-sex genetic correlation
281 significantly less than 1 (FDR<5%; average genetic correlation: 0.92), consistent with previous
282 results²². On average, these interactions explained 2.6% of trait variance across all traits
283 analyzed. The lowest significant genetic correlation was 0.66 for WHRadjBMI²², explaining
284 17% of trait variance. Traits assigned to Scenario 2 (Varying genetic variance) are reported in
285 **Figure 5b** and **Supplementary Table 9**. We identified 12 traits with significant PRSxSex
286 interaction (FDR<5%) and a significant SNP-heritability by Sex test (FDR<5%). On average,
287 these interactions explained 1.4% of trait variance across all traits; the variance explained by
288 GxSex effects was larger for binary traits than for quantitative traits (see **Discussion**). The
289 largest PRSxSex interaction was for type 2 diabetes, explaining 0.39% of trait variance. Traits
290 assigned to Scenario 3 (Proportional amplification) are reported in **Figure 5c** and
291 **Supplementary Table 9**. We identified 8 traits with significant PRSxSex interaction (FDR<5%)
292 but a non-significant SNP-heritability by Sex test (FDR<5%). On average, these interactions
293 explained 0.05% of trait variance across all traits analyzed (a very small contribution). Of the 30
294 traits implicated across three scenarios, we identified 7 traits assigned to both Scenario 1 and
295 Scenario 2, and 5 traits assigned to both Scenario 1 and Scenario 3 (**Supplementary Table 9**).
296 We also identified 2 traits with a significant SNP-heritability x Sex test but non-significant
297 PRSxSex interaction (**Supplementary Table 10**); our primary interpretation is that this is due to
298 changes in environmental variance rather than GxSex interaction (**Methods**).

299

300 Examples of traits with significant GxSex assigned to each Scenario are reported in
301 **Figure 6** and **Supplementary Table 11**. First, neuroticism was assigned to Scenario 1 (**Figure**
302 **6a**). The Genetic correlation approach estimated a cross-sex genetic correlation of 0.90, which is
303 significantly less than 1 (P=3.5e-9; FDR < 5%), explaining 5.0% of the variance of neuroticism.
304 On the other hand, the PRSxSex regression approach (P=0.58) and SNP-heritability by Sex
305 approach (P=0.45) produced non-significant results. We note that males had lower prevalence of
306 neuroticism than females (1.6% vs. 2.3% in top score for neuroticism, P<1e-16), as previously
307 reported⁴². Second, All autoimmune disease was assigned to Scenario 2 (**Figure 6b**). The
308 PRSxSex regression approach (P=2e-15) and SNP-heritability by Sex approach (SNP-heritability
309 (liability scale) of 23% for males and 18% for females; P<1e-16) both produced significant
310 results (FDR < 5%), explaining 4.9% of the variance of All autoimmune disease (vs. SNP-
311 heritability of 19%). On the other hand, the genetic correlation approach produced a non-
312 significant result (P=0.03). We note that males had lower prevalence of All autoimmune disease
313 than females (7.2% vs. 16%, P<1e-16), as previously reported⁴³. Third, HDL cholesterol was
314 assigned to Scenario 3 (**Figure 6c**). The PRSxSex regression approach produced a significant
315 result (P<2e-16; FDR < 5%), explaining 0.4% of the variance of HDL cholesterol. On the other

316 hand, the SNP-heritability by Sex approach ($P=0.09$) was not significant. However, the genetic
317 correlation approach estimated a cross-sex genetic correlation of 0.93, which is significantly less
318 than 1 ($P=5e-6$; $FDR < 5\%$), explaining 3.5% of the variance of HDL cholesterol (Scenario 1);
319 this implies that multiple types of GxSex interaction impact HDL cholesterol. We note that
320 males had 0.83 s.d. lower HDL cholesterol than females ($P<1e-16$).

321

322 In summary, we detected GxSex interaction in each of the three scenarios across the 33
323 diseases/traits analyzed. We estimate that these GxSex effects explain 4.0% of disease/trait
324 variance across all traits analyzed (s.e. 1.1% across traits), compared to SNP-heritability of 29%
325 (s.e. 3%).

326

327 Discussion

328

329 We have applied three statistical approaches to detect, quantify, and distinguish the genome-
330 wide contributions of three different types of GxE interaction (**Figure 1a**) across 33 UK Biobank
331 diseases/traits, analyzing 10 E variables spanning lifestyle, diet, and other environmental
332 exposures as well as biological sex. We determined that GxE interactions (involving these E
333 variables) and GxSex interactions each explained a significant fraction of phenotypic variance,
334 representing an appreciable contribution to disease/trait architectures. It is possible that GxE
335 interactions involving E variables not studied here could explain even more phenotypic variance.

336

337 Our finding of distinct explanations underlying GxE interactions (**Figure 1a**) motivates a
338 unified model consistent with this finding. We propose a model in which GxE occurs at different
339 levels of a hierarchy that leads from genetic variants to pathways to disease (**Supplementary**
340 **Figure 5**). In this model, Scenario 1 (Imperfect genetic correlation) occurs when an E variable
341 modifies the effects of individual variants (or sets of variants), differentially impacting different
342 parts of the genome; Scenario 2 (Varying genetic variance) occurs when an E variable modifies
343 all of the pathways underlying genetic risk, uniformly impacting genetic variance; and Scenario
344 3 (Proportional amplification) occurs when an E variable modifies all aspects of disease biology,
345 proportionately impacting both genetic and environmental variance. Under this model, an E
346 variable can modify any point along the hierarchy from genetic variants to pathways to disease.
347 Further investigation and validation of this model is a direction for future research.

348

349 Our study represents an advance over previous studies investigating genome-wide GxE.
350 First, we distinguish three different types of GxE interaction: Imperfect genetic correlation,
351 Varying genetic variance, and Proportional amplification (**Figure 1a**; also see **Supplementary**
352 **Figure 5**). Second, most variance components methods for detecting genome-wide GxE^{13–15,17,18}
353 cannot detect genome-wide GxE unless SNP-heritability varies across E bins (Scenario 2). An
354 exception is GxEMM¹⁶, which detects other types of GxE by explicitly modeling genetic and
355 environmental variance that varies with the E variable; however, GxEMM is less
356 computationally tractable and generally less powerful than our framework (**Supplementary**
357 **Figure 2**). Third, variance components methods that assume independence between G and GxE
358 effects are susceptible to bias if G and GxE effects are correlated, but our statistical approaches
359 are robust to this possibility (**Supplementary Figure 3**). Fourth, previous methods have not been
360 applied at biobank scale across a broad range of disease/traits; the statistical approaches that we
361 propose are computationally scalable to very large data sets (see **Methods**), enabling our

362 biobank-scale analyses implicating 60 trait-E pairs with significant GxE and 30 traits with
363 significant GxSex. Fifth, a recent study reported that GxSex acts primarily through
364 amplification²⁴ (Scenario 2 and Scenario 3), but our analyses of GxSex determined that
365 Imperfect genetic correlation (Scenario 1) explained a larger proportion of trait variance than
366 amplification; in addition, ref. ²⁴ did not estimate contributions to trait variance and did not
367 distinguish between Scenario 2 and Scenario 3, as we do here.

368
369 Our study has several implications. First, our results narrow the search space of disease/traits
370 and E variables for which genome-wide association studies of GxE interactions are most likely to
371 be fruitful; in particular, trait-E pairs with substantial trait variance explained by Scenario 1
372 (Imperfect genetic correlation) (**Supplementary Table 5**) should be prioritized for locus-specific
373 analyses, in preference to trait-E pairs with trait variance explained by Scenario 2 or Scenario 3.
374 Second, our results imply that there is broad potential to improve polygenic risk scores (PRS) by
375 leveraging information on E variables in training and/or test samples⁴⁴. Third, there is broad
376 potential to prioritize individuals for which a lifestyle intervention to modify an E variable would
377 be most effective based on their genetic profile. Fourth, previous work has suggested that
378 population-specific causal effect sizes in functionally important regions may be caused by
379 GxE⁴⁵, motivating efforts to partition the imperfect genetic correlations across E bins that we
380 have identified across functionally important regions. Fifth, the significant contribution of GxE
381 to disease/trait architectures—even when restricting to the limited set of E variables that we
382 analyzed here—implicates GxE effects as a factor in “missing heritability”, defined as the gap
383 between estimates of SNP-heritability³⁰ and estimates of narrow-sense heritability⁴⁶ (e.g. from
384 twin studies⁴⁷); although GxE effects are not included in the *definition* of narrow-sense
385 heritability, they can inflate twin-based *estimates* of narrow-sense heritability, analogous to GxG
386 effects⁴⁸. All of these implications motivate directions for future research.

387
388 Our study has several limitations. First, our analyses assess GxE and GxSex interaction for
389 binary traits on the observed scale (and then transform estimates to the liability scale), consistent
390 with prevailing approaches for variance component analysis of binary traits^{31–34}. This approach
391 leads to much larger variance explained by GxE and GxSex for binary traits vs. quantitative traits
392 in Scenario 2 (**Supplementary Table 12**; also see **Figure 3b** and **Figure 5b**). These statistical
393 interactions may not be indicative of biological interactions, as previously noted in the context of
394 both GxE interaction² and GxG interaction⁴⁹. Directly modeling GxE interaction on the liability
395 scale^{50,51} is an important direction for future research, and may produce different findings.
396 Second, the E variables that we analyzed comprise an extremely limited subset of the set of E
397 variables that may contribute to GxE effects (and their values may be subject to measurement
398 error); even when GxE effects are detected, the implicated E variable may be tagging an
399 unmeasured causal E variable with larger GxE effects. Third, our use of PRSxE regression to
400 detect GxE is limited by the accuracy of PRS and may require larger training sample sizes
401 (enabling more accurate PRS) to be well-powered, particularly for less heritable diseases/traits.
402 The average accuracy of the PRS across traits in the held-out set of 49K individuals was 9.2%, as
403 measured by r^2 between predicted and true phenotypes (**Supplementary Table 3**). Fourth, our
404 estimates of the trait variance explained by GxE effects detected via PRSxE analyses assume that
405 PRSxE effects extrapolate linearly to GxE effects (**Methods**); we believe that this is a reasonable
406 assumption, but we cannot formally exclude the possibility that genetic effects captured by PRS
407 interact differently with an E variable than genetic effects not captured by PRS. Fifth, most of the

408 E variables that we study are weakly heritable (**Supplementary Table 4**), raising the possibility
409 of GxG (rather than GxE) effects; we consider GxG to be an unlikely explanation given the E
410 variables' low SNP-heritabilities, but we cannot formally exclude this possibility. Sixth, our use
411 of PRSxE regression to detect GxE may be anti-conservative due to unmodeled
412 heteroskedasticity³⁷; however, we obtained nearly identical results using Huber-White variance
413 estimators (also known as robust regression^{38,39}) (**Supplementary Table 6**), suggesting that this
414 does not impact our findings. We note that we observe many instances of differences in trait
415 variance across E variables (**Supplementary Table 7**), but these alone are not indicative of GxE
416 interactions. Seventh, our use of PRSxE regression to detect GxE may produce false positives if
417 there is a nonlinear relationship between E and trait value; we included an E^2 term in PRSxE
418 regressions to ameliorate this possibility but determined that inclusion or exclusion of the E^2
419 term had little impact on our results (**Supplementary Table 13**), suggesting that nonlinear
420 effects do not greatly impact our findings. Eighth, we have analyzed British-ancestry samples
421 from the UK Biobank, but an important future direction is to extend our analyses to cohorts of
422 diverse genetic ancestry^{52,53}, which may differ in their distributions of E variables, tagging of
423 causal E variables by measured E variables, and/or causal GxE effects (analogous to differences
424 in main G effects^{45,54}). Eighth, we do not analyze GxAge interaction (and we note the limited age
425 variation in UK Biobank samples; age = 55 ± 8 years), but we highlight GxAge interaction and
426 longitudinal data as important directions for future research^{51,55,56}. Despite these limitations, our
427 work quantifies and distinguishes three different types of GxE interaction across a broad set of
428 diseases/traits and E variables.

429

430 **Code Availability**

431

432 Cross trait LDSC: <https://github.com/bulik/ldsc>

433 BOLT-LMM: <https://alkesgroup.broadinstitute.org/BOLT-LMM/downloads/>

434 PRSxE regression: Will be added upon publication.

435 Code to reproduce analysis: Will be added upon publication.

436

437 **Data Availability**

438

439 We will make the results of the three statistical approaches we use here publicly available upon
440 publication.

441

442 **Acknowledgements**

443

444 We are grateful to Martin Zhang, Ben Strober, Xilin Jiang, and Jordan Rossen for helpful
445 discussions and Sriram Sankararaman and Ali Pazokitoroudi for comments on an earlier version
446 of this manuscript. This research was conducted using the UK Biobank resource under
447 application no. 16549 and funded by National Institutes of Health (NIH) grants R01 MH101244,
448 R37 MH107649 and R01 HG006399. The funders had no role in study design, data collection
449 and analysis, decision to publish or preparation of the manuscript.

450

451 **Methods**

452

453 *Data sources and preprocessing*

454
455 We used data from the UK Biobank in all our analyses. For polygenic score-based analyses that
456 required a training and testing dataset, we used a set of 337K unrelated white British individuals
457 for training²⁷. For testing, we used a set of 49K European individuals who are unrelated to each
458 other and to the training cohort²⁷. Note that while “testing” typically refers to a setting where the
459 ultimate goal is to assess PRS accuracy, here we use it to refer to the set of samples we in which
460 we run a regression of phenotype on PRSxE and covariates. We used polygenic scores generated
461 by ref.²⁷. We used the linear scoring function in Plink v1.9⁵⁷ to compute polygenic scores in the
462 set of 49K test individuals.

463
464 *Choice of diseases/traits and environmental variables*

465
466 We chose a set of 33 diseases/traits with SNP heritability Z scores > 6 and squared genetic
467 correlation less than 0.5 (**Supplementary Table 3, Supplementary Table 4**). We chose a set of
468 10 E variables, including 5 previously analyzed E variables from ref.¹⁴ and 5 additional E
469 variables (Air pollution, time spent napping, sleeplessness, Diet, wheat consumption)
470 (**Supplementary Figure 4**).

471
472 To compute the Diet variable, we performed PCA on a covariance matrix consisting of several
473 diet variables: cooked vegetable intake, salad intake, fresh fruit intake, processed meat intake,
474 poultry intake, beef intake, pork intake, coffee intake (**Supplementary Figure 6**). We used the
475 function `prcomp` in R and extracted the first PC.

476
477 *Genetic correlation approach to detecting GxE*

478
479 We performed GWAS using BOLT-LMM²⁶ within bins of E variables. Then, we used bivariate
480 LD Score regression³⁶ to estimate the genetic correlation between the top and bottom quintiles of
481 E variables; for binary E variables, we estimated the genetic correlation between individuals in
482 each E bin. We used imputed SNPs with MAF > 0.01% and used the `--no-intercept` option to
483 increase our power. Computed a Z score testing against the null hypothesis that the genetic
484 correlation is 1 as:

485

$$Z = \frac{1 - \hat{r}_g}{\widehat{se}}$$

486
487 *PRSxE regression approach to detecting GxE*

488
489 Our PRSxE regression takes the following form:

490

$$Y = PRS + E + PRS * E + C\#$$

491
492 where Y is the trait value, PRS is the polygenic score for the trait (see *Data sources and*
493 *preprocessing*), E is the environment variable, and C is a set of covariates. For all analyses, we
494 correct for the following covariates: age, sex, 10 genetic PCs computed in the held-out set, the
495 squared E variable: E², age*sex, E*age, E*sex. We carried out this regression using the Python
496 package `statsmodels` v0.14. We also compute a ‘base’ model, which is the same regression

497 without the PRSxE term. We use the p-value associated with the PRSxE term in the interaction
498 model to assess significance.

499
500 To test whether our results were driven by heteroskedasticity, we performed the same analysis
501 using robust standard errors as implemented in statsmodels using the ‘H1’ covariance matrix
502 (Supplementary Table 12).

503
504 We note the PRSxE regression test is not expected to produce a significant finding if the
505 environmental variance changes as a function of E but the genetic variance does not change as a
506 function of E, because the PRS does not measure changes in environmental variance.

507
508 *SNP-heritability by E approach to detecting GxE*

509
510 We used BOLT-REML³³ v2.3.6 to compute heritability in bins of E variables.

511 To test for a significant difference in heritability between two bins, we computed a Z score as:

512

$$Z = \frac{h_1^2 - h_2^2}{\sqrt{\sigma_1^2 + \sigma_2^2}}$$

513 where 1 and 2 index the E bins.

514

515 *False Discovery Rate (FDR) control*

516

517 We chose a 5% FDR control separately for each statistical approach (Genetic correlation, PRSxE
518 regression, and SNP-heritability by E) using the qvalue R package⁵⁸. We ensured our one-sided
519 test against a null genetic correlation of 1 did not produce a skewed P-value distribution, which
520 could indicate improper choice of a one-sided test. We chose to control the FDR separately for
521 GxE and GxSex analyses because we expected the proportional of truly null tests to be different
522 between GxE and GxSex. In particular, we expected to find more truly positive GxSex tests
523 given previous studies^{22,24}. Consistent with this, we found the qvalue procedure for estimating
524 the proportion of truly null hypotheses failed in the GxSex analyses and we had to set the
525 proportion of true null tests (π_0) to 1, which is equivalent to the Benjamini-Hochberg
526 procedure⁵⁹. Story and Tibshirani⁶⁰ argue this is much more conservative than the qvalue
527 procedure. Our choice to control each E variable together is conservative, but accounts for non-
528 zero correlations between E variables.

529

530 *Classification of trait-E pairs into Scenarios*

531

532 We combined the results of the three statistical approaches to classify trait-E pairs into 3 distinct
533 scenarios. We classified trait-E pairs into Scenario 1 if the Genetic correlation was significantly
534 less than 1. We classified trait-E pairs into Scenario 2 if the SNP-heritability by E and PRSxE
535 regression approaches were significant. We classified trait-E pairs into Scenario 3 if the PRSxE
536 regression approach was significant but the SNP-heritability by E approach was not significant.
537 It is possible that the SNP-heritability by E approach is significant but the PRSxE regression
538 approach is not significant, which should not be viewed as an instance of GxE because the SNP-
539 heritability difference may be driven by changes to the environmental variance rather than the
540 genetic variance. In addition, it is possible for trait-E pairs to be classified into both Scenario 1

541 and Scenario 2, or both Scenario 1 and Scenario 3, but not both Scenario 2 and Scenario 3
542 because significance or non-significance of the SNP-heritability by E approach are mutually
543 exclusive.

544

545 *Scalability of statistical approaches*

546

547 We consider the scalability of the three statistical approaches we use here. First, there is the
548 computational cost of producing the input to our statistical approaches. For the genetic
549 correlation test, this consists of running GWAS in bins of E variables. There are many scalable
550 approaches for this, including BOLT-LMM²⁶, regenie⁶¹, and fastGWA⁶². For PRSxE regression,
551 this consists of computing PRS weights. There are many scalable approaches for this including
552 BOLT-LMM²⁶, PRScs⁶³, SBayesR⁶⁴, and LDpred2⁶⁵. SNP-heritability by E does not require
553 generating additional input. In these analyses, we use BOLT-LMM for GWAS, which has a
554 runtime that scales with O(MN), where M is the number of SNPs and N is the sample size of
555 individuals. For PRSxE regression we use weights computed by Weissbrod et al 2022²⁷, who did
556 not publish an analysis of runtime. Second, there is the computational cost of the statistical
557 approaches themselves. For genetic correlation, we use cross-trait LDSC²⁵, which runs in
558 seconds (< 30s for the SNP sets that we analyze here). For PRSxE regression, we use a multiple
559 regression, which also runs in seconds (< 30s for the sample size that we analyze here). For SNP-
560 heritability by E, we use BOLT-REML³³, which has a runtime that scales with O(MN).

561

562 *Simulations*

563

564 To test the power of each approach, we simulated 1,000 replicates of each scenario. In all cases,
565 we simulated two E bins and varied the parameters according to the respective generative
566 models. For each replicate, we simulated $M=10,000$ causal SNPs with effect sizes drawn from a
567 specified distribution. We generated unlinked genotypes with binomial sampling from an allele
568 frequency of 0.5.

569

570 We simulated causal effect sizes for each scenario as follows:

571

572 Scenario 1

$$\begin{bmatrix} \beta_1 \\ \beta_2 \end{bmatrix} \sim N \left(\begin{bmatrix} 0 \\ 0 \end{bmatrix}, \begin{bmatrix} \sigma_g^2/M & \gamma/M \\ \gamma/M & \sigma_g^2/M \end{bmatrix} \right)$$

573

574 We simulated $\sigma_g^2 = 0.25$ and varied γ to produce genetic correlations
575 $r_g \in \{1, 0.99, 0.98, 0.97, 0.96, 0.95, 0.94\}$.

576

577 Scenario 2

$$\begin{bmatrix} \beta_1 \\ \beta_2 \end{bmatrix} \sim N \left(\begin{bmatrix} 0 \\ 0 \end{bmatrix}, \begin{bmatrix} \sigma_{g,1}^2/M & \sigma_{g1}\sigma_{g2}/M \\ \sigma_{g1}\sigma_{g2}/M & \sigma_{g,2}^2/M \end{bmatrix} \right)$$

578

579

580 We simulated $\sigma_{g1}^2=0.25$ and set σ_{g2}^2 to produce a difference in heritability:

581 $\{0, 0.01, 0.02, 0.03, 0.04, 0.05\}$. Our choice of covariance ensures the genetic correlation is one.

582
583 Scenario 3
584

$$\begin{bmatrix} \beta_1 \\ \beta_2 \end{bmatrix} \sim N \left(\begin{bmatrix} 0 \\ 0 \end{bmatrix}, \begin{bmatrix} \sigma_g^2/M & \sigma_g^2/M \\ \sigma_g^2/M & \sigma_g^2/M \end{bmatrix} \right)$$

585
586 We set $\sigma_g^2 = 0.25$. To simulate proportional amplification, we multiplied the phenotypes for
587 individuals in environment 2 by a constant: $\{1.0, 1.025, 1.05, 1.075, 1.1\}$.

588
589 Using the simulated causal effect sizes, we simulated GWAS effect size estimates as:

$$\hat{\beta}_1 \sim N \left(\beta_1, \frac{(1 - h_1^2)/M}{N} \right)$$

590
591
$$\hat{\beta}_2 \sim N \left(\beta_2, \frac{(1 - h_2^2)/M}{N} \right)$$

592
593 where 1 and 2 index the environments and N denotes GWAS sample size. We estimate h_g^2 from
594 the simulated causal effect sizes by first computing the χ^2 statistic ($\chi^2 := N * \hat{\beta}^2$), then
595 computing $h_g^2 = \frac{M}{N} E[\chi^2 - 1]$, where E denotes the mean computed over the independent
596 SNPs²⁵.

597 We compute the genetic correlation as:

$$r_g = \frac{\hat{\beta}_1^T \hat{\beta}_2}{\sqrt{\hat{h}_{g,1}^2 * \hat{h}_{g,2}^2}}$$

598
599 where T denotes the transpose. We compute standard errors for the estimates using a jackknife
600 over SNPs, where we leave out one SNP at a time because they are independent.

601
602 To simulate PRSxE, we first simulated causal effect sizes for 10,000 independent SNPs. Then,
603 we compute PRS weights analytically as:

604
$$\beta_{PRS} = \left(\frac{h_g^2}{h_g^2 + \frac{M}{N}} \right) \hat{\beta}.$$

605
606 This simple shrinkage estimator can be interpreted as the posterior mean causal effect size under
607 a normal prior (in the special case of no LD), and is similar to the posterior mean causal effect
608 size under a point-normal prior (in the special case of no LD) when the genetic architecture is
609 highly polygenic⁶⁶, as simulated here.

610
611 We estimate h_g^2 without knowledge of the E bins, mimicking estimation of SNP-heritability
612 across the 337K individuals; we estimate h_g^2 as the sum of squared standardized effect sizes
613 (averaged across E bins).

614

615 We also evaluated the performance of GxEMM in detecting GxE in Scenarios 1, 2, and 3. We
616 followed the simulation framework in the original publication and simulated 1,000 causal SNPs
617 and 10,000 individuals. We simulated a binary E variable and drew SNP effects according to
618 each Scenario. We performed two tests within the GxEMM framework: 1) IID versus Hom,
619 which tests for polygenic GxE under homoscedasticity, and 2) Free versus Hom, which test for
620 polygenic GxE allowing for heteroskedasticity. We performed a Wald test as implemented in
621 GxEMM and compared the point estimates of heritability in the free model to the simulated
622 heritability in each of the environments. We performed 100 simulation replicates.


623
624 To compare GxEMM with our tests, we simulated data under the same framework with matched
625 sample sizes. Specifically, for genetic correlation and SNP-heritability x E, we simulated 5,000
626 individual per E bin (total N=10,000). For PRSxE, we used a training set sample size of 337K,
627 which matches the real data, and a held out set of N=10,000.

628

629 *Estimation of trait variance explained*


630

631 For trait-E pairs in Scenario 1, we compute the trait variance explained by GxE as $(1 - r_g)/2$ for
632 binary E variables (where r_g is the genetic correlation between the two E bins) (**Supplementary**
633 **Note**) and $\frac{1-r_g}{10}$ for continuous E variables (where r_g is the genetic correlation between the top
634 and bottom quintiles of E values). To obtain the transformation for continuous E variables, we
635 used our simulations (see above) to examine the relationship between estimated genetic
636 correlation and the variance explained by GxE. We found when we binned the E variable into 5
637 bins and computed the genetic correlation between the top and bottom bins, the transformation
638 $\frac{1-r_g}{10}$ produced accurate estimates of the variance explained by GxE. For trait-E pairs in Scenarios
639 2 or 3, we divide the variance explained by the PRSxE regression term by the variance explained
640 by the PRS and multiply by the SNP-heritability. We verified these scaling procedures produce
641 accurate estimates of the excess variance explained by GxE in simulations (**Supplementary**
642 **Figure S3**). For Scenario 1, we simulated a continuous E variable with mean 0 and variance 1
643 for 337K individuals. We simulated main genetic effects drawn from a normal distribution with
644 mean 0 and variance 0.25 and environment interaction effects from a normal distribution with
645 mean 0 and variance across a range of parameters (1e-1 to 1e-5) for 5,000 SNPs. We binned
646 individuals into 5 bins and ran a GWAS in the top and bottom bins and compute the genetic
647 correlation between the bins. Then, we scaled the estimates according to the formula above
648 (**Supplementary Figure S3a**). For Scenarios 2 and 3, we simulated 1,000 causal SNPs from a
649 normal distribution with mean 0 and variance 0.25. We simulated a continuous E variable with
650 mean 0 and variance 1 for 49K individuals. We set the amplification parameter to 0.1 and
651 generated phenotypes according to Eq. 1 (*Overview of methods*). We performed GWAS and
652 estimated PRS weights as in the *Simulations* section. Then, we ran the PRSxE test and computed
653 the variance explained. We then compared this to the true variance explained (**Supplementary**
654 **Figure S3b, S3c**). This scaling assumes that PRSxE effects linearly extrapolate to GxE effects.
655 We do not use the estimates of differences in SNP-heritability by E to estimate the variance
656 explained by GxE. When reporting average variance explained per trait, we computed the R^2 for
657 each trait using a model including all marginally significant (FDR < 5%) interaction terms for
658 that trait (**Supplementary Table 14**).




659
660
661
662
663

Figure 1. Overview of 3 GxE Scenarios and statistical approaches to detect and distinguish between them. (a) Relative values of genetic (blue) and environmental (orange) variance in each Scenario. (b) Statistical approaches to detect and distinguish between each Scenario. (c) Flow chart for classifying results into Scenarios.




664
665
666
667
668
669
670
671

Figure 2. Detecting and distinguishing between 3 Scenarios of GxE interaction in simulations. Rows denote 3 Scenarios (1-3), and columns denote 3 statistical approaches. (a) Proportion of significant tests for Scenario 1 (Imperfect genetic correlation) across 3 statistical approaches. (b) Proportion of significant tests for Scenario 2 (varying genetic variance) across 3 statistical approaches. (c) Proportion of significant tests for Scenario 3 (proportional amplification) across 3 statistical approaches. Error bars denote standard deviations across 100 simulation replicates. Numerical results are reported in **Supplementary Table 1**.




672
 673 **Figure 3. Detecting, quantifying, and distinguishing between 3 Scenarios of GxE**
 674 **interaction across 33 diseases/traits and 10 E variables.** Diseases/traits are reported on the y-
 675 axis and estimates of excess variance explained by GxE are reported on the x-axis. Only
 676 significant results are reported (FDR < 5% across traits and E variables, computed separately for
 677 each Scenario). For diseases/traits with multiple significant E variables in a given Scenario,
 678 results for each significant E variable are reported separately using bars with smaller thickness.
 679 (a) Results for trait-E pairs in Scenario 1: Imperfect genetic correlation. (b) Results for trait-E
 680 pairs in Scenario 2: Varying genetic variance; we note that BMI has significant GxE for
 681 Townsend deprivation (red), physical activity (purple), and alcohol consumption (black). (c)
 682 Results for trait-E pairs in Scenario 3: Proportional amplification. Numerical results are reported
 683 in **Supplementary Table S5**.




684
685 **Figure 4. Examples of 3 Scenarios of GxE interaction.** (a) White blood cell count x smoking
686 status is consistent with Scenario 1: Imperfect genetic correlation. (b) Type 2 diabetes x alcohol
687 consumption is consistent with Scenario 2: Varying genetic variance. (c) Waist-to-hip ratio
688 adjusted for BMI x Time spent watching TV is consistent with Scenario 3: Proportional
689 amplification. Numerical results are reported in **Supplementary Table S8**.

690
691
692



693
694 **Figure 5. Detecting, quantifying, and distinguishing between 3 Scenarios of GxSex**
695 **interaction across 33 diseases/traits.** Diseases/traits are reported on the y-axis and estimates of
696 excess variance explained by GxSex are reported on the x-axis. Only significant results are
697 reported (FDR < 5% across traits, computed separately for each Scenario). (a) Results for traits
698 in Scenario 1: Imperfect genetic correlation. (b) Results for traits in Scenario 2: Varying genetic
699 variance. (c) Results for traits in Scenario 3: Proportional amplification. Numerical results are
700 reported in **Supplementary Table S9**.

701
702



703
704 **Figure 6. Examples of 3 Scenarios of GxSex interaction.** (a) Neuroticism x Sex is consistent
705 with Scenario 1: Imperfect genetic correlation. (b) All autoimmune disease x Sex is consistent
706 with Scenario 2: Varying genetic variance. (c) HDL Cholesterol x Sex is consistent with
707 Scenario 1 and Scenario 3. Numerical results are reported in **Supplementary Table S11**.
708

709 **References**

- 710 1. Hunter, D. J. Gene–environment interactions in human diseases. *Nat. Rev. Genet.* **6**, 287–298
711 (2005).
- 712 2. Thomas, D. Gene-Environment-Wide Association Studies: Emerging Approaches. *Nat. Rev.*
713 *Genet.* **11**, 259–272 (2010).
- 714 3. Franks, P. W. & McCarthy, M. I. Exposing the exposures responsible for type 2 diabetes and
715 obesity. *Science* **354**, 69–73 (2016).
- 716 4. Li, J., Li, X., Zhang, S. & Snyder, M. Gene-Environment Interaction in the Era of Precision
717 Medicine. *Cell* **177**, 38–44 (2019).
- 718 5. Hu, Z. *et al.* A genome-wide association study identifies two new lung cancer susceptibility
719 loci at 13q12.12 and 22q12.2 in Han Chinese. *Nat. Genet.* **43**, 792–796 (2011).
- 720 6. Wu, C. *et al.* Genome-wide association analyses of esophageal squamous cell carcinoma in
721 Chinese identify multiple susceptibility loci and gene-environment interactions. *Nat. Genet.*
722 **44**, 1090–1097 (2012).
- 723 7. Young, A. I., Wauthier, F. & Donnelly, P. Multiple novel gene-by-environment interactions
724 modify the effect of FTO variants on body mass index. *Nat. Commun.* **7**, 12724 (2016).
- 725 8. Yang, J. *et al.* FTO genotype is associated with phenotypic variability of body mass index.
726 *Nature* **490**, 267–272 (2012).
- 727 9. Shungin, D. *et al.* Ranking and characterization of established BMI and lipid associated loci as
728 candidates for gene-environment interactions. *PLOS Genet.* **13**, e1006812 (2017).
- 729 10. Young, A. I., Wauthier, F. L. & Donnelly, P. Identifying loci affecting trait variability
730 and detecting interactions in genome-wide association studies. *Nat. Genet.* **50**, 1608–1614
731 (2018).

- 732 11. Wang, H. *et al.* Genotype-by-environment interactions inferred from genetic effects on
733 phenotypic variability in the UK Biobank. *Sci. Adv.* **5**, eaaw3538 (2019).
- 734 12. Westerman, K. E. *et al.* Variance-quantitative trait loci enable systematic discovery of
735 gene-environment interactions for cardiometabolic serum biomarkers. *Nat. Commun.* **13**, 3993
736 (2022).
- 737 13. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide
738 complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
- 739 14. Robinson, M. R. *et al.* Genotype–covariate interaction effects and the heritability of adult
740 body mass index. *Nat. Genet.* **49**, 1174–1181 (2017).
- 741 15. Moore, R. *et al.* A linear mixed-model approach to study multivariate gene–environment
742 interactions. *Nat. Genet.* **51**, 180–186 (2019).
- 743 16. Dahl, A. *et al.* A Robust Method Uncovers Significant Context-Specific Heritability in
744 Diverse Complex Traits. *Am. J. Hum. Genet.* **106**, 71–91 (2020).
- 745 17. Kerin, M. & Marchini, J. Inferring Gene-by-Environment Interactions with a Bayesian
746 Whole-Genome Regression Model. *Am. J. Hum. Genet.* **107**, 698–713 (2020).
- 747 18. Di Scipio, M. *et al.* A versatile, fast and unbiased method for estimation of gene-by-
748 environment interaction effects on biobank-scale datasets. *Nat. Commun.* **14**, 5196 (2023).
- 749 19. Traglia, M. *et al.* Genetic Mechanisms Leading to Sex Differences Across Common
750 Diseases and Anthropometric Traits. *Genetics* **205**, 979–992 (2017).
- 751 20. Khramtsova, E. A., Davis, L. K. & Stranger, B. E. The role of sex in the genomics
752 of human complex traits. *Nat. Rev. Genet.* **20**, 173–190 (2019).
- 753 21. Kamitaki, N. *et al.* Complement genes contribute sex-biased vulnerability in diverse
754 disorders. *Nature* **582**, 577–581 (2020).

- 755 22. Bernabeu, E. *et al.* Sex differences in genetic architecture in the UK Biobank. *Nat. Genet.*
756 **53**, 1283–1289 (2021).
- 757 23. Khramtsova, E. A. *et al.* Quality control and analytic best practices for testing genetic
758 models of sex differences in large populations. *Cell* **186**, 2044–2061 (2023).
- 759 24. Zhu, C. *et al.* Amplification is the primary mode of gene-by-sex interaction in complex
760 human traits. *Cell Genomics* **3**, (2023).
- 761 25. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.
762 *Nat. Genet.* **47**, 1236–1241 (2015).
- 763 26. Loh, P.-R., Kichaev, G., Gazal, S., Schoech, A. P. & Price, A. L. Mixed-model
764 association for biobank-scale datasets. *Nat. Genet.* **50**, 906–908 (2018).
- 765 27. Weissbrod, O. *et al.* Leveraging fine-mapping and multipopulation training data to
766 improve cross-population polygenic risk scores. *Nat. Genet.* **54**, 450–458 (2022).
- 767 28. Rask-Andersen, M., Karlsson, T., Ek, W. E. & Johansson, Å. Gene-environment
768 interaction study for BMI reveals interactions between genetic factors and physical activity,
769 alcohol consumption and socioeconomic status. *PLoS Genet.* **13**, e1006977 (2017).
- 770 29. Marderstein, A. R. *et al.* Leveraging phenotypic variability to identify genetic
771 interactions in human phenotypes. *Am. J. Hum. Genet.* **108**, 49–67 (2021).
- 772 30. Yang, J. *et al.* Common SNPs explain a large proportion of the heritability for human
773 height. *Nat. Genet.* **42**, 565–569 (2010).
- 774 31. Lee, S. H., Wray, N. R., Goddard, M. E. & Visscher, P. M. Estimating missing
775 heritability for disease from genome-wide association studies. *Am. J. Hum. Genet.* **88**, 294–
776 305 (2011).

- 777 32. Lee, S. H. *et al.* Estimating the proportion of variation in susceptibility to schizophrenia
778 captured by common SNPs. *Nat. Genet.* **44**, 247–250 (2012).
- 779 33. Loh, P.-R. *et al.* Contrasting genetic architectures of schizophrenia and other complex
780 diseases using fast variance-components analysis. *Nat. Genet.* **47**, 1385–1392 (2015).
- 781 34. Pazokitoroudi, A. *et al.* Efficient variance components analysis across millions of
782 genomes. *Nat. Commun.* **11**, 4020 (2020).
- 783 35. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
784 *Nature* **562**, 203 (2018).
- 785 36. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
786 polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
- 787 37. Voorman, A., Lumley, T., McKnight, B. & Rice, K. Behavior of QQ-Plots and Genomic
788 Control in Studies of Gene-Environment Interaction. *PLOS ONE* **6**, e19416 (2011).
- 789 38. Huber, P. J. The behavior of maximum likelihood estimates under nonstandard
790 conditions. in *Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and*
791 *Probability, Volume 1: Statistics* vol. 5.1 221–234 (University of California Press, 1967).
- 792 39. White, H. A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct
793 Test for Heteroskedasticity. *Econometrica* **48**, 817–838 (1980).
- 794 40. Pedersen, K. M. *et al.* Smoking and Increased White and Red Blood Cells. *Arterioscler.*
795 *Thromb. Vasc. Biol.* **39**, 965–977 (2019).
- 796 41. Baliunas, D. O. *et al.* Alcohol as a Risk Factor for Type 2 Diabetes. *Diabetes Care* **32**,
797 2123–2132 (2009).
- 798 42. Wendt, F. R. *et al.* Sex-Specific Genetic and Transcriptomic Liability to Neuroticism.
799 *Biol. Psychiatry* **93**, 243–252 (2023).

- 800 43. Whitacre, C. C. Sex differences in autoimmune disease. *Nat. Immunol.* **2**, 777–780
801 (2001).
- 802 44. Mostafavi, H. *et al.* Variable prediction accuracy of polygenic scores within an ancestry
803 group. *eLife* **9**, e48376 (2020).
- 804 45. Shi, H. *et al.* Population-specific causal disease effect sizes in functionally important
805 regions impacted by selection. *Nat. Commun.* **12**, 1098 (2021).
- 806 46. Visscher, P. M., Hill, W. G. & Wray, N. R. Heritability in the genomics era--concepts
807 and misconceptions. *Nat. Rev. Genet.* **9**, 255–266 (2008).
- 808 47. Polderman, T. J. C. *et al.* Meta-analysis of the heritability of human traits based on fifty
809 years of twin studies. *Nat. Genet.* **47**, 702–709 (2015).
- 810 48. Zuk, O., Hechter, E., Sunyaev, S. R. & Lander, E. S. The mystery of missing heritability:
811 Genetic interactions create phantom heritability. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 1193–
812 1198 (2012).
- 813 49. Cordell, H. J. Detecting gene-gene interactions that underlie human diseases. *Nat. Rev.*
814 *Genet.* **10**, 392–404 (2009).
- 815 50. Zaitlen, N. *et al.* Informed Conditioning on Clinical Covariates Increases Power in Case-
816 Control Association Studies. *PLOS Genet.* **8**, e1003032 (2012).
- 817 51. Jiang, X., Holmes, C. & McVean, G. The impact of age on genetic risk for common
818 diseases. *PLOS Genet.* **17**, e1009723 (2021).
- 819 52. Kanai, M. *et al.* Genetic analysis of quantitative traits in the Japanese population links
820 cell types to complex human diseases. *Nat. Genet.* **50**, 390–400 (2018).
- 821 53. All of Us Research Program Investigators *et al.* The ‘All of Us’ Research Program. *N.*
822 *Engl. J. Med.* **381**, 668–676 (2019).

- 823 54. Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health
824 disparities. *Nat. Genet.* **51**, 584 (2019).
- 825 55. Dey, R. *et al.* Efficient and accurate frailty model approach for genome-wide survival
826 association analysis in large-scale biobanks. *Nat. Commun.* **13**, 5437 (2022).
- 827 56. Pedersen, E. M. *et al.* ADuLT: An efficient and robust time-to-event GWAS. *Nat.*
828 *Commun.* **14**, 5553 (2023).
- 829 57. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
830 datasets. *GigaScience* **4**, s13742-015-0047-8 (2015).
- 831 58. qvalue: Q-value estimation for false discovery rate control. (2023).
- 832 59. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
833 Powerful Approach to Multiple Testing. *J. R. Stat. Soc. Ser. B Methodol.* **57**, 289–300 (1995).
- 834 60. Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. *Proc. Natl.*
835 *Acad. Sci. U. S. A.* **100**, 9440–9445 (2003).
- 836 61. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative
837 and binary traits. *Nat. Genet.* **53**, 1097–1103 (2021).
- 838 62. Jiang, L. *et al.* A resource-efficient tool for mixed model association analysis of large-
839 scale data. *Nat. Genet.* **51**, 1749–1755 (2019).
- 840 63. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via
841 Bayesian regression and continuous shrinkage priors. *Nat. Commun.* **10**, 1776 (2019).
- 842 64. Lloyd-Jones, L. R. *et al.* Improved polygenic prediction by Bayesian multiple regression
843 on summary statistics. *Nat. Commun.* **10**, 5086 (2019).
- 844 65. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger. *Bioinformatics*
845 **36**, 5424–5431 (2021).


846 66. Vilhjálmsón, B. J. *et al.* Modeling Linkage Disequilibrium Increases Accuracy of
847 Polygenic Risk Scores. *Am. J. Hum. Genet.* **97**, 576–592 (2015).

848

849


850
851
852

Supplementary Material




853
854
855
856
857
858
859
860

Figure S1 Results of 3 statistical approaches for detecting GxE in null simulations with no GxE. (a) Proportion of significant tests for genetic correlation across 3 scenarios. (b) Proportion of significant tests for PRSxE regression across 3 scenarios. (c) Proportion of significant tests for SNP-heritability by E across 3 scenarios. Error bars denote standard deviations across 100 simulation replicates.




861
862
863
864
865
866

Figure S2 Comparison of three statistical approaches for detecting GxE to ExEMM in simulations. a) Scenario 1 with varying true genetic correlation across E, b) Scenario 2 with varying heritability in the second environment, c) Scenario 3 with phenotypic amplification across E bins.




867
868
869
870
871
872

Figure S3 Accuracy of estimates of excess trait variance explained by GxE interaction in simulations. a) genetic correlation in Scenario 1, b) PRS_xE in Scenario 2, and c) PRS_xE in Scenario 3. For all plots, the black line corresponds to the $y=x$ line and the x and y axes are both on a log scale.




873
 874 **Figure S4 Phenotypic correlations between E variables.** X denotes non-significant
 875 comparisons at a p-value threshold of 0.05/11.



876
877
878
879
880
881
882

Figure S5 Conceptual model linking three scenarios of GxE. Scenario 1 can be conceptualized as E variables modifying the effects of independent loci. Scenario 2 can be conceptualized as modifying pathways which aggregate the genetic effects of many loci, resulting in a scaling of genetic effects. Finally, Scenario 3 can be conceptualized as modifying the total genetic liability.



883
884 **Figure S6 Phenotypic correlations of diet variables used to construct a composite Diet**
885 **variable.** Each cell in the heatmap shows the correlation between the measured diet variable on
886 the X axis and the measured diet variable on the Y axis. All correlations are significant at a
887 Bonferroni corrected p-value threshold of 0.05.

888
889 **Supplementary Table 1 Numerical results of Detecting and distinguishing between 3**
890 **Scenarios of GxE interaction in simulations.** For each statistical approach and scenario, we
891 report the proportion of significant tests and standard deviation across replicates.

892
893 **Supplementary Table 2 Simulations showing bias induced by correlated G and GxE effects.**
894 We tested the impact of correlated G and GxE effects on variance component estimates when
895 assuming that G and GxE effects are not correlated. We set the true variance of G effects to 0.1
896 and the true variance of GxE effects to 0.1. We varied the correlation of the G and GxE effects

897 and simulated values for 100,000 individuals. We estimate the variance explained by G and GxE
898 using ANOVA in R and report the bias (estimated effect - true effect).

899

900 **Supplementary Table 3 Description of the 33 UK Biobank traits analyzed.** For each trait we
901 report a detailed name, the GWAS sample size (including number of cases for binary traits), the
902 SNP-heritability (liability scale for binary traits), and the PRS accuracy (R^2 ; observed scale for
903 binary traits).

904

905 **Supplementary Table 4 SNP-heritability of E variables studied here.** We estimated SNP-
906 heritability using LDSC. For the composite diet variable, we report the SNP-heritability for each
907 of the underlying variables that make up the composite diet variable. P-values test against a null
908 of zero SNP-heritability.

909

910 **Supplementary Table 5 Numerical results of Detecting, quantifying, and distinguishing**
911 **between 3 Scenarios of GxE interaction across 33 diseases/traits and 10 E variables.** For
912 each trait-E pair (A, B), we report (C) the excess variance explained by PRSxE and (D) the
913 associated q value, (E) the difference in heritability between the top and bottom bins of the E
914 variables and (F) the associated q value, (G) the genetic correlation between the top and bottom
915 bin of the E variable and (H) the associated q value. We also assign each trait-E pair to the three
916 scenarios (I, J, K).

917

918 **Supplementary Table 6 P-values using robust regression in PRSxE regression analysis**
919 **compared to P-value from the main PRSxE regression analysis.** For each trait-E pair, we
920 report (A) p-value and (B) effect size for the main PRSxE regression and (C, D) using the Huber-
921 White variance estimator (robust regression).

922

923 **Supplementary Table 7 SNP-heritability differences for trait-E pairs with no PRSxE**
924 **interaction.** For each trait-E pair with a significant difference in SNP-heritability and no
925 significant PRSxE interaction we report the SNP-heritability difference and q-value at 5% FDR
926 control.

927

928 **Supplementary Table 8 Numerical results of Examples of 3 Scenarios of GxE interaction.**
929 We report detailed results for 3 trait-E pairs reported in Figure 4. For each trait-E pair (A, B), we
930 report (C) the genetic correlation and (D) p-value, (E) PRSxE regression coefficient and (F) p-
931 value, (G, H, I, J, K) SNP-heritability across bins of the E variable with associated standard error
932 and (L) the p-value testing for a difference between the top and bottom bins of the E variable.

933

934 **Supplementary Table 9 Numerical results of Detecting, quantifying, and distinguishing**
935 **between 3 Scenarios of GxSex interaction across 33 diseases/traits.** For each trait (A, B), we
936 report (C) the excess variance explained by PRSxSex and (D) the associated q value, (E) the
937 difference in heritability between males and females and (F) the associated q value, (G) the
938 genetic correlation between males and females and (H) the associated q value. We also assign
939 each trait-E pair to the three scenarios (I, J, K).

940

941 **Supplementary Table 10 SNP-heritability differences for trait-sex pairs with no PRSxSex**
942 **interaction.** For each trait-sex pair with a significant difference in SNP-heritability and no

943 significant PRSxSex interaction we report the SNP-heritability difference and q-value at 5%
944 FDR control.

945
946 **Supplementary Table 11 Numerical results of Examples of 3 Scenarios of GxSex**
947 **interaction.** We report detailed results for 3 trait-sex pairs reported in Figure 4. For each trait (A,
948 B), we report (C) the genetic correlation and (D) p-value, (E) PRSxE regression coefficient and
949 (F) p-value, (G, H, I, J, K) SNP-heritability across sex with associated standard error and (L) the
950 p-value testing for a difference between the top and bottom bins of the E variable.

951
952 **Supplementary Table 12 Average variance explained by binary and quantitative traits.** For
953 each scenario, we report the average trait variance explained by binary, quantitative, and all traits
954 for both GxE and GxSex interactions.

955
956 **Supplementary Table 13 PRSxE regression results including a non-linear E term.** For each
957 trait-E pair, we report (A) P-value and (B) effect size including E^2 as a covariate and (C, D) not
958 including E^2 as a covariate.

959
960 **Supplementary Table 14 Trait variance explained by GxE interactions with multiple E**
961 **variables.** For traits with multiple marginally significant E variable interactions, we report the
962 variance explained by a joint model with all marginally significant E variables.

963
964 **Supplementary Note for “Distinct explanations underlie gene-environment interactions in**
965 **the UK Biobank”**